Dr. Anu G. Gaba, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 36
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 301
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
ND license 9598 · MN license 47654
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Sanford Medical Center Fargo Fargo, ND
- Essentia Health Fargo, ND
- Perham Health Perham, MN
- Jamestown Regional Medical Center Jamestown, ND
- Sanford Hillsboro Hillsboro, ND
Medical groups
- Sanford Medical Center Fargo (1,225 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 301
- Services billed
- 5,882
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 248 | 157 |
| Established patient office or other outpatient visit, 40-54 minutes | 126 | 69 |
| Established patient office or other outpatient visit, 20-29 minutes | 105 | 82 |
| New patient office or other outpatient visit, 45-59 minutes | 12 | 12 |
| New patient office or other outpatient visit, 60-74 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Fargo, ND | 286 |
| Anastrozole Other prescribers in Fargo, ND | 143 |
| Tamoxifen Citrate Other prescribers in Fargo, ND | 119 |
| Alendronate Sodium Other prescribers in Fargo, ND | 71 |
| Prednisone Other prescribers in Fargo, ND | 36 |
| Eliquis (apixaban) Other prescribers in Fargo, ND | 36 |
| Dexamethasone Other prescribers in Fargo, ND | 31 |
| Oxybutynin Chloride Other prescribers in Fargo, ND | 28 |
| Exemestane | 25 |
| Hydroxyurea Other prescribers in Fargo, ND | 24 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $120 in total to this clinician.
| Tempus Ai, Inc | $94.09 |
|---|---|
| Pfizer Inc. | $26.00 |
| Food and Beverage | $94.09 |
|---|---|
| Education | $26.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Jun 23, 2025 | Education PADCEV · ONCOLOGY · in-kind | $26.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $17,757 in research payments for these studies, mostly to the institutions running them.
- A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER)
Novartis Pharmaceuticals Corporation - A randomized phase 3 double-blinded study comparing the efficacy and s
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.